ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio Corporation today announced it will present data from two separate Phase 1 clinical trials at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Boston, Mass. from Sept. 12-15. The presentation details are as follows:
Poster Presentation G1-197, #206 – “Phase I Study of a Nanoemulsion Adjuvanted Nasal Influenza Vaccine Demonstrates Both Mucosal and Systemic Immune Responses in Humans”
Date: Sunday, Sept. 12 at 11:30 a.m. ET
During the presentation, NanoBio will share clinical data demonstrating that its nanoemulsion adjuvanted intranasal flu vaccine, NB-1008:
Poster Presentation L1-1751, #436 – “Evaluation of the Safety and Efficacy of a Novel Anti-Acne Nanoemulsion (NB-003) in a Randomized, Open-Label, Parallel-Group, Single Center Study”
Date: Tuesday, Sept. 14 at 11:15 a.m. ET
During the presentation, NanoBio will share clinical data demonstrating that its topical bactericidal oil-in-water emulsion, NB-003:
NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.